The goal of this proposal was to determine if microRNA’s (miR) are elevated in the plasma of individuals affected by the inherited peripheral neuropathy Charcot-Marie-Tooth Disease, type 1A (CMT1A)
A new test may spur advances in drug discovery for a rare and debilitating neurological disorder. Charcot-Marie-Tooth disease, a rare inherited neurological disorder, affects more than 2.8 million people around the globe.
Defining the full spectrum of human disease associated with a biomarker is necessary to advance the biomarker into clinical practice. We hypothesize that associating biomarker measurements with EHR populations based on shared genetic architectures would establish the clinical epidemiology of the biomarker.